Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the 'Company', 'Arcturus', Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025.
Arcturus Therapeutics First Quarter 2025 Earnings Conference Call
Domestic: 1-800-267-6316
International: 1-203-518-9783
Conference ID: ARCTURUS
Webcast: Link
About Arcturus
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Canada promises to boost defense spending, meet NATO target much earlier
By Wa Lone TORONTO (Reuters) -Canada's Liberal government will pour extra billions into its armed forces and hit NATO's 2% military spending target this fiscal year, five years earlier than promised, Prime Minister Mark Carney said on Monday. Canada has been under pressure from the United States and other NATO allies for years to increase military funding. Canada currently spends about 1.4% of GDP on defense. "Now is the time to act with urgency, force, and determination," Carney said in a speech in Toronto, reiterating promises to work more closely with Europe's defense industry. Carney won the April 28 election on a promise to stand up to U.S. President Donald Trump's tariffs and also to reduce the country's military reliance on Washington. Carney said another reason for Ottawa to act was what he called the decision by the United States to gradually withdraw from the concept of collective security. "Rising great powers are now in strategic competition with America. A new imperialism threatens. Middle powers compete for interests and attention, knowing that if they are not at the table, they will be on the menu," he said. The previous Liberal government last year formally committed to hit the NATO target by 2032. During the election campaign Carney pledged to get to 2% by 2030. Canada will boost pay for the armed forces and buy new submarines, aircraft, ships, armed vehicles and artillery, as well as new radar, drones and sensors to monitor the sea floor and the Arctic, Carney said. "The transformation of our military capabilities can help transform our economy," he said. Officials are due to give more details of the plan before Carney speaks to the media at 1 p.m. Eastern Time (1700 GMT). (Additional reporting by Nilutpal Timsina in Bengaluru and Promit Mukherjee; writing by David Ljunggren; editing by Rod Nickel)
Yahoo
31 minutes ago
- Yahoo
Fungi concerns spark nationwide recall of Zicam® and Orajel™ products
(WJW) – According to the U.S. Food and Drug Administration, Church & Dwight Co., Inc. is voluntarily recalling some Zicam® and Orajel™ products because fungi could be present in the items' cotton swab components. The recalled products include all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. Consumers are advised to 'immediately' stop using the recalled products. Major grocery chain slashing prices for the summer 'Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries,' reads the recall alert. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' The FDA said, so far, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico, said the FDA. Brain-eating amoeba: How are people infected? Here's the specific details to check for: Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. You can view images of the recalled products in the slideshow below: 'This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall,' states the FDA on its website. Consumers can CLICK HERE or call (800) 981-4710 for refund details. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
32 minutes ago
- Business Wire
Wolters Kluwer Updates Sentri7, Enhancing Pharmacy and Nursing Workflows
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health today announced extensive updates to its Sentri7 ® Drug Diversion and Sentri7 ® Pharmacy solutions, reinforcing its commitment to innovation in medication safety, compliance, and patient care. These improvements further equip clinical teams with actionable, data-driven insights to streamline workflows for drug diversion and medication management, ultimately supporting better patient care. 'Our mission is to help healthcare organizations deliver safer, higher-quality care with solutions that optimize the workflows supporting patient care and compliance in today's demanding healthcare environment,' said Karen Kobelski, Vice President and General Manager of Clinical Surveillance Compliance & Data Solutions at Wolters Kluwer Health. " With our team's deep expertise in pharmacy, technology, and artificial intelligence, we're providing customers with critical insights and support to address challenges like medication management, drug diversion prevention, and the opioid crisis.' Sentri7 Drug Diversion delivers improved workflows The redesigned Sentri7 Drug Diversion solution introduces a more intuitive interface, enabling teams to detect and manage drug diversion threats with greater precision and efficiency. Healthcare organizations can now act faster and more effectively to mitigate risks, with features like: User-friendly dashboard: Consolidates essential risk factors and actionable insights into a single, user-friendly interface to streamline diversion detection follow-up. Refined HEAT™ scoring and trend analysis: Quickly identifies high-risk staff across multiple facilities with a Watch List that improves alert monitoring of priority areas of concern. Missing medication analysis: Saves time for busy nursing teams by reconciling medication transactions across care areas, enabling timely interventions. 'Sentri7 Drug Diversion has a very mature user interface. It is very straightforward. It is easy to use and train our diversion staff to use. The graphics are very clear to understand. The solution has a HEAT score that it gives when it suspects an employee of diversion. It promotes that information to us and tells us where there is suspicious activity rather than us having to look at the numbers and determine that on our own,' according to a pharmacy manager interviewed by KLAS Research, February 2025. Sentri7 Pharmacy updates support patient-centered care The updated Sentri7 Pharmacy solution delivers an efficient, patient-centric workflow to optimize medication therapies, safety and overall cost savings. Key updates include: User-friendly interface: Tailored to support rounding workflows for individual patients, in addition to managing targeted medication surveillance across the entire patient population. Enhanced documentation tools: Simplified and standardized data entry enhances reporting, enabling pharmacy teams to demonstrate impact with evidence-based metrics. Actionable Performance Insights: Provides clear key performance indicators on cost savings, departmental contributions, and patient outcomes. When asked about Wolters Kluwer's surveillance solution, one pharmacy analyst noted in a KLAS Research April 2025 interview, 'Wolters Kluwer is super engaging and allows for a lot of collaborative work with organizations. The vendor does a good job of meeting organizations where they are at and working toward solutions. Wolters Kluwer has just been great at engaging with end users on how to improve their Sentri7 Pharmacy Surveillance product. I would definitely recommend Sentri7 Pharmacy Surveillance.' Learn more about the enhanced Sentri7 solutions. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
